Cyclacel Pharmaceuticals, Inc. (CYCC) Posts Mixed Q3 Results
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Join SI Premium – FREE
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported Q3 EPS of ($0.07), $0.01 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $159 thousand versus the consensus estimate of $180 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
- PepsiCo (PEP) Misses Q2 EPS by 1c, Beats on Revenue
- Simply Good Foods (SMPL) Tops Q3 EPS by 7c; offers outlook
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
